Showing 1 - 10 of 14
Background: Several treatment options are available for patients with type 2 diabetes mellitus who are making the transition from oral antidiabetes drugs (OADs) to insulin. Two options currently recommended by the Canadian Diabetes Association for initiating insulin therapy in patients with type...
Persistent link: https://www.econbiz.de/10008462723
Background: Assessments of vaccination programmes should account for several important factors, including efficacy, safety and costs of preventing and treating the disease. Because patients with invasive meningococcal disease (IMD) are managed primarily in an inpatient setting, hospital costs...
Persistent link: https://www.econbiz.de/10010614287
Background Patients with diabetes mellitus have been shown to be at high risk for both macrovascular and microvascular complications (MVC). Recent studies have focused on MVC and their effect on the healthcare system, but limited published data exist on long-term costs associated with MVC in...
Persistent link: https://www.econbiz.de/10004964196
Background: Recent meta-analyses in the published medical literature have found improved glycaemic control with continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) of insulin for patients with diabetes mellitus. In Australia, CSII is predominantly used...
Persistent link: https://www.econbiz.de/10005590431
Background:Background: Canadian patients, healthcare providers and payers share interest in assessing the value of self-monitoring of blood glucose (SMBG) for individuals with type 2 diabetes but not on insulin. Using the UKPDS (UK Prospective Diabetes Study) model, the Canadian Optimal...
Persistent link: https://www.econbiz.de/10010614285
Background: There is a lack of a uniform proxy for defining direct medical costs in the US. This potentially important source of variation in modelling and other types of economic studies is often overlooked. The extent to which increased expenditures for an intervention can be offset by...
Persistent link: https://www.econbiz.de/10005041940
Schizophrenia is a serious and complex disorder, with treatment requiring a large number and wide range of health and social service resources. This paper addresses one challenge for assessing the direct costs of antipsychotic treatments - that of interpreting both cost and effectiveness...
Persistent link: https://www.econbiz.de/10005449096
Persistent link: https://www.econbiz.de/10009124317
Persistent link: https://www.econbiz.de/10012491012
Persistent link: https://www.econbiz.de/10011660132